PBX1 identified as a new pioneer factor underlying progression in breast cancer

The presence of a new pioneer factor, known as PBX1, can guide the response to estrogen in breast cancer cells according to researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center in results published on November 17 in the open-access journal PLoS Genetics. This research reveals that PBX1 alone can determine the risk of the spread of cancer in patients with estrogen receptor alpha (ERα)-positive breast cancer, which accounts for about two-thirds of all breast cancers diagnosed in North America.

Pioneer factors are an emerging class of chromatin remodelers with the capacity to modulate cellular identity as they set the stage by defining the genomic regions accessible for transcription factors. "Since cancer is characterized by a loss of cell-fate identity, it is not surprising that other pioneer factors have already been characterized as oncogenic factors in breast cancer, but PBX1 is one that discriminates progression," said Dr. Mathieu Lupien, assistant professor of genetics, Norris Cotton Cancer Center, Dartmouth Medical School, who served as principal investigator for the study. Specifically, this research demonstrates that PBX1 directly modulates chromatin compaction at discrete genomic regions to promote the recruitment of the transcription factor ERα, driving the proliferative response to estrogen in .

"Unfortunately, numerous ERα-positive patients with breast cancer progress to more advanced stages of the disease as they develop resistance to endocrine therapies, which directly target ERα." said lead author Dr. Luca Magnani, post-doctoral scientist.

"This work may rapidly translate to the clinic because PBX1 could likely serve as a prognostic marker for ERα-positive breast cancer progression. It also highlights the potential therapeutic benefit of developing means to antagonize pioneer factors such as PBX1 to prevent progression" said Dr. Lupien.

More information: Magnani L, Ballantyne EB, Zhang X, Lupien M (2011) PBX1 Genomic Pioneer Function Drives ERa Signaling Underlying Progression in Breast Cancer. PLoS Genet 7(11): e1002368. doi:10.1371/journal.pgen.1002368

add to favorites email to friend print save as pdf

Related Stories

Coffee reduces breast cancer risk: new study

May 11, 2011

Recently published research shows that coffee drinkers enjoy not only the taste of their coffee but also a reduced risk of cancer with their cuppa. More detailed research published today in BioMed Central's open access journal ...

Recommended for you

Mutation disables innate immune system

7 hours ago

A Ludwig Maximilian University of Munich team has shown that defects in the JAGN1 gene inhibit the function of a specific type of white blood cells, and account for a rare congenital immune deficiency that ...

Study identifies genetic change in autism-related gene

Aug 28, 2014

A new study from Bradley Hospital has identified a genetic change in a recently identified autism-associated gene, which may provide further insight into the causes of autism. The study, now published online in the Journal of ...

NIH issues finalized policy on genomic data sharing

Aug 27, 2014

The National Institutes of Health has issued a final NIH Genomic Data Sharing (GDS) policy to promote data sharing as a way to speed the translation of data into knowledge, products and procedures that improve health while ...

The genes behind the guardians of the airways

Aug 27, 2014

Dysfunctions in cilia, tiny hair-like structures that protrude from the surface of cells, are responsible for a number of human diseases. However the genes involved in making cilia have remained largely elusive. ...

User comments